ECU Libraries Catalog

Accelerating the development of new drugs and diagnostics : maximizing the impact of the cures acceleration network / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.

Other author/creatorOlson, Steve, 1956-
Other author/creatorClaiborne, Anne B.
Other author/creatorInstitute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation.
Format Electronic and Book
Publication InfoWashington, D.C. : National Academies Press, ©2012.
Description1 online resource (1 PDF file (xv, 115 pages))
Supplemental Content Direct link to resource
Contents Introduction -- Approaches to accelerating translational science -- Application of matching authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.
Summary This public workshop considered options and opportunities to maximize the usefulness and impact of the Cures Acceleration Network (CAN) program in order to advance translational sciences. The workshop objectives were to:1. Identify and catalog potential tools, methods, and approaches that hold promise for accelerating translational science.-- Consideration of such promising approaches will draw from the experiences of existing activities at other federal agencies related to the goals of CAN--for example, FDA, the U.S. Centers for Disease Control and Prevention (CDC), and the Agency for Healthcare Research and Quality (AHRQ).2. Discuss the authorities conferred to CAN and identify strategies for effectively using those authorities.-- Consideration of the CAN authorities will specifically explore the flexible research, or "other transaction," authority and will reference existing efforts in which such authority is currently applied across other federal agencies--for example, DARPA, the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).3. Explore promising models for public-private collaborations that could be strengthened or facilitated by activities under CAN.-- Discuss barriers to such collaborations and identify opportunities and potential solutions for moving past the identified barriers.-- Discuss the respective roles of multiple sectors, including, for example, the pharmaceutical and biotechnology industries, venture capital and private equity, and patient advocacy groups.4. Identify barriers and potential solutions to facilitate coordination of activities under CAN with the FDA regulatory review process and timelines.
Bibliography noteIncludes bibliographical references.
Funding informationThis study was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and HHSF223001003T), Abbott Pharmaceuticals, American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, Bristol-Myers Squibb, Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly & Co., FasterCures, Foundation for the NIH, Friends of Cancer Research, GlaxoSmithKline, Janssen Research & Development, LLC, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.
Issued in other formPrint version: Accelerating the development of new drugs and diagnostics. Washington, D.C. : National Academies Press, ©2012 9780309261166

Available Items

Library Location Call Number Status Item Actions
Electronic Resources Access Content Online ✔ Available